Pharma

Your Article Summary

See Latest Articles

Merck Revises Regulatory Filing Timeline for MK-0524B, an Investigational Fixed-Dose Combination of MK-0524A and Simvastatin
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/02/06

Merck & Co., Inc. revised its filing plans for MK-0524B, its investigational fixed-dose combination of MK-0524A (a DP-1 selective inhibitor coupled with extended-release niacin) and simvastatin (ZOCOR(1)), confirming it will not file a worldwide marketing application in 2007

Today in Regulatory Issues...keeping you current

Receive free subspecialty "5-minute updates" via email

Two Delivery Systems Win Baldrige Award
HealthDataManagement, 12/18/09

Advisory Committee briefing materials for CRESTOR sNDA available on US FDA web site
AstraZeneca, 12/15/09

Sixteen Fired for Records Snooping
HealthDataManagement, 12/09/09

 See all of Regulatory Issues